Innovative Acne Foam from Arkin and Foamix
“We are delighted to establish this innovative partnership with Foamix,” said Mori Arkin, Chairman and CEO of Arkin Holdings. “With its strong development capabilities and focus on dermatological disorders, we believe Foamix is an excellent partner to help advance the development of this exciting program.”
“We are very proud to partner with Arkin”, said Foamix CEO Dr. Dov Tamarkin. “We feel strongly that our unique foams will help revolutionize the dermatological marketplace, enabling noticeable, short-term results and increased user satisfaction,” he added.
Acne is the most common skin problem, affecting more than 80 percent of young adults and teenagers. The global prescription acne market was worth $2.8 billion in 2010. It is estimated to reach revenues in excess of $3 billion by 2016. Foam is a preferred delivery system for acne drugs. It is preferred by users for facial treatment, due to its easy spreading and quick absorption; and it is also useful for the treatment of back and chest acne.
About Foamix
Foamix Ltd (foamix.co.il) is a clinical-stage specialty pharma company, focused on the development of proprietary topical foam products, with improved convenience, higher compliance and better efficacy. The Company’s technologies are backed by an extensive patent portfolio. The company’s development capabilities range from initial development of the formulations to scale-up, GMP manufacturing, preclinical and clinical studies. Foamix has a strong in-house pipeline of dermatological and gynecological drugs. The Company’s lead product, Topical Minocycline, is currently in Phase II clinical studies.
To date, Foamix has 9 issued patents in the United States, covering its foam and OilGel technology platforms. The company has an additional 150 applications and patents worldwide, of which more than 60 applications are filed in the U.S.
See Also:
If you enjoyed this post, please consider leaving a comment, subscribe to the feed and get future articles delivered to your feed reader or follow us on Twitter.
Comments
No comments yet.
Leave a comment